RT Journal Article
SR Electronic
T1 Continued Emergence and Evolution of Omicron in South Africa: New BA.4 and BA.5 lineages
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.01.22274406
DO 10.1101/2022.05.01.22274406
A1 Houriiyah Tegally
A1 Monika Moir
A1 Josie Everatt
A1 Marta Giovanetti
A1 Cathrine Scheepers
A1 Eduan Wilkinson
A1 Kathleen Subramoney
A1 Sikhulile Moyo
A1 Daniel G. Amoako
A1 Cheryl Baxter
A1 Christian L. Althaus
A1 Ugochukwu J. Anyaneji
A1 Dikeledi Kekana
A1 Raquel Viana
A1 Jennifer Giandhari
A1 Richard J. Lessells
A1 Tongai Maponga
A1 Dorcas Maruapula
A1 Wonderful Choga
A1 Mogomotsi Matshaba
A1 Simnikiwe Mayaphi
A1 Nokuzola Mbhele
A1 Mpaphi B. Mbulawa
A1 Nokukhanya Msomi
A1 NGS-SA consortium
A1 Yeshnee Naidoo
A1 Sureshnee Pillay
A1 Tomasz Janusz Sanko
A1 James E. San
A1 Lesley Scott
A1 Lavanya Singh
A1 Nonkululeko A. Magini
A1 Pamela Smith-Lawrence
A1 Wendy Stevens
A1 Graeme Dor
A1 Derek Tshiabuila
A1 Nicole Wolter
A1 Wolfgang Preiser
A1 Florette K. Treurnicht
A1 Marietjie Venter
A1 Michaela Davids
A1 Georginah Chiloane
A1 Adriano Mendes
A1 Caitlyn McIntyre
A1 Aine O’Toole
A1 Christopher Ruis
A1 Thomas P. Peacock
A1 Cornelius Roemer
A1 Carolyn Williamson
A1 Oliver G. Pybus
A1 Jinal Bhiman
A1 Allison Glass
A1 Darren P. Martin
A1 Andrew Rambaut
A1 Simani Gaseitsiwe
A1 Anne von Gottberg
A1 Tulio de Oliveira
YR 2022
UL http://medrxiv.org/content/early/2022/05/02/2022.05.01.22274406.abstract
AB South Africa’s fourth COVID-19 wave was driven predominantly by three lineages (BA.1, BA.2 and BA.3) of the SARS-CoV-2 Omicron variant of concern. We have now identified two new lineages, BA.4 and BA.5. The spike proteins of BA.4 and BA.5 are identical, and comparable to BA.2 except for the addition of 69-70del, L452R, F486V and the wild type amino acid at Q493. The 69-70 deletion in spike allows these lineages to be identified by the proxy marker of S-gene target failure with the TaqPath™ COVID-19 qPCR assay. BA.4 and BA.5 have rapidly replaced BA.2, reaching more than 50% of sequenced cases in South Africa from the first week of April 2022 onwards. Using a multinomial logistic regression model, we estimate growth advantages for BA.4 and BA.5 of 0.08 (95% CI: 0.07 - 0.09) and 0.12 (95% CI: 0.09 - 0.15) per day respectively over BA.2 in South Africa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the South African Medical Research Council (SAMRC) with funds received from the National Department of Health. Sequencing activities for NICD are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (CDC)(grant number 5 U01IP001048-05-00; 1 NU51IP000930-01-00); the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); and the UK Department of Health and Social Care and managed by the Fleming Fund and performed under the auspices of the SEQAFRICA project. This research was also supported by The Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the CDC and the COVID International Task Force (ITF) funds through the CDC under the terms of a subcontract with the African Field Epidemiology Network (AFENET) AF-NICD-001/2021. Sequencing activities at KRISP and CERI are supported in part by grants from the World Health Organization, the Abbott Pandemic Defense Coalition (APDC), the National Institute of Health USA (U01 AI151698) for the United World Antivirus Research Network (UWARN) and the INFORM Africa project through IHVN (U54 TW012041), and the South African Department of Science and Innovation (SA DSI) and the SAMRC under the BRICS JAF #2020/049Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee (ref. BREC/00001510/2020), the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M180832), Stellenbosch University HREC (ref. N20/04/008 COVID-19) and the University of Cape Town HREC (ref. 383/2020). Individual participant consent was not required for the genomic surveillance. This requirement was waived by the Research Ethics Committees.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at GISAID database.